EuropaBio sees the Directive on cross-border healthcare as an important instrument to ensure patient access to the best available care. The Directive is particularly relevant for advanced therapies and medicines for rare diseases.
We do appreciate the efforts led by the FAIR Initiative and hope to continue to partner with ACCELERATE to speed up the delivery of innovative therapies to children and adolescents.
On the occasion of World PI Week we interviewed Johan Prevot, Executive Director of the International Patient Organisation for Primary Immunodeficiencies (IPOPI).